VLTO arrives at Tuesday's earnings call having already delivered its answer to the positioning question — the stock is up 9.2% on the week and 4.4% on Monday alone, trading at $98.47 and closing in on the Street's mean price target of $107.
The call-heavy options skew that defined both of last week's previews has not only held — it has deepened. The put/call ratio ticked up slightly to 0.066 on Tuesday but remains well below its 20-day average of 0.103, running roughly 1.2 standard deviations on the bullish side. That persistence is notable: the PCR spent most of June and early July above 0.13, then collapsed and has stayed down even through the July 24 quarterly report and the subsequent rally. Call buyers did not take profits into strength. The borrow market offers no counterweight — availability is extraordinarily loose at roughly 4,361% of short interest, meaning the lending pool is effectively unlimited. Short interest at 2.8% of the float is modest and has been range-bound for weeks, while borrowing costs have dropped 24% over the past week to under 0.40%. There is no meaningful short-side pressure in this name.
The fundamental debate has not shifted much since the prior previews, but the stock's move adds a new layer of complexity. Bulls focus on the 5.1% organic revenue growth trajectory, North American momentum, and a recurring-revenue mix from consumables and services that provides earnings visibility. Stifel raised its target to $111 nine days ago, reiterating Buy — the only bellwether-adjacent move in the past two weeks. Bears point to the 10 basis-point adjusted operating margin compression to 23.9% and the risk that slowing industrial demand or supply chain friction erodes the profitability story. At a P/E just under 21 and EV/EBITDA around 15.4, valuation has re-rated upward with the stock — the multiple has expanded roughly 0.8 turns over the past 30 days, leaving less room for error on the margin line.
One institutional footnote worth noting: T. Rowe Price added roughly 4.1 million shares in its most recent filing, a meaningful addition that now places the firm among the top five holders. BlackRock also nudged its position higher. That buying backdrop, combined with the call skew and the near-absence of short conviction, suggests the institutional base has been leaning into the recovery rather than hedging against it.
The print will test whether the margin compression that defined Q4 2025 was a trough or the beginning of a trend — and whether Veralto's guidance is strong enough to justify a stock now trading within striking distance of analyst targets after a near-10% weekly move.
See the live data behind this article on ORTEX.
Open VLTO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
